Format

Send to

Choose Destination
Pharmgenomics Pers Med. 2014 Nov 15;7:357-65. doi: 10.2147/PGPM.S53163. eCollection 2014.

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.

Author information

1
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA ; Weill Cornell Medical College, New York, NY, USA.

Abstract

T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ligands (PD-L1, PD-L2) suppress the activity of T-lymphocytes. Advances in the understanding of immunology and its role in cancer have led to the development of immune checkpoint inhibitors that block CTLA-4 and PD-1 and result in durable responses in patients with a wide range of cancers. PD-1 and PD-L1 inhibitors are currently in many stages of clinical investigation, and the anti-PD-1 antibody, pembrolizumab, was recently approved by the US Food and Drug Administration. Many questions remain to be answered, such as the optimal administration schedule, biomarkers that associate with benefit, and potential for use of PD-1 agents in combination approaches. Nonetheless, immunotherapy with PD-1 blocking antibodies is now becoming an integral part in the management of cancer.

KEYWORDS:

cytotoxic T-lymphocyte antigen 4; immune checkpoints; immunotherapy; programmed cell death protein-1

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center